Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O75586
UPID:
MED6_HUMAN
Alternative names:
Activator-recruited cofactor 33 kDa component; Mediator complex subunit 6; Renal carcinoma antigen NY-REN-28
Alternative UPACC:
O75586; B4DU17; B4E2P0; O15401; Q53FE3; Q53HJ3; Q6FHQ4; Q9BTH1; Q9UHL1
Background:
Mediator of RNA polymerase II transcription subunit 6, also known as Activator-recruited cofactor 33 kDa component, Mediator complex subunit 6, and Renal carcinoma antigen NY-REN-28, plays a pivotal role in the transcription of RNA polymerase II-dependent genes. It acts as a crucial component of the Mediator complex, facilitating the transfer of information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. This protein is instrumental in the assembly of a functional preinitiation complex, incorporating RNA polymerase II and general transcription factors.
Therapeutic significance:
Understanding the role of Mediator of RNA polymerase II transcription subunit 6 could open doors to potential therapeutic strategies.